August 2012
-
Pneumagen has announced the initiation of a Phase 1 SAD/MAD study of its Neumifil carbohydrate binding module (mCBM) nasal spray, which the company is developing for the prevention and treatment of viral respiratory infections. The… Read more . . .
-
Birmingham Biotech said that it has licensed a carrageenan/gellan antiviral nasal spray from the University of Birmingham and intends to market the spray in the UK and in Asian countries for protection against COVID-19 starting… Read more . . .
-
According to Pulmatrix, a dispute between Pulmatrix and Cipla over funding related to the development of Pulmazole intraconazole DPI (PUR 1900) has been resolved. In May 2021, Pulmatrix announced that Cipla had failed to provide… Read more . . .
-
According to Liquidia, the FDA has tentatively approved the company’s NDA for its Yutrepia (LIQ861) treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH). The FDA had previously issued a complete response letter to… Read more . . .
-
According to EffRx Pharmaceuticals, Swissmedic has approved Bronchitol inhaled dry powder mannitol as an add-on to other medications for the treatment of cystic fibrosis in patients 6 years old and older. EffRx acquired Swiss rights… Read more . . .
-
Covis Pharma will pay AstraZeneca $270 million for global rights to the Eklira (Turdorza, Bretaris) aclidinium bromide and Duaklir (Brimica) aclidinium bromide/formoterol DPIs, the companies have announced. Both DPIs are marketed for the treatment of COPD. In addition to… Read more . . .
-
Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray… Read more . . .
-
Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company’s common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata,… Read more . . .
-
According to TFF Pharmaceuticals, Health Canada has issued a no objection letter regarding a Phase 1 clinical trial of TFF’s dry powder inhaled niclosamide that will evaluate 0.5, 2, and 6 mg doses in healthy volunteers… Read more . . .
-
Inhaler testing equipment company Copley Scientific is introducing a new nasal dose uniformity sampling apparatus (DUSA) interface plate designed to work with the company’s Vertus II/Plus shake and fire system for delivered dose uniformity testing… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.